UnitedHealth profits rising; Optum revenues up — 5 key points

United Health Group, the largest health insurer in the U.S., released promising numbers for the first quarter of fiscal 2015.

Advertisement

Here are five key points from the company’s first-quarter earnings statement.

1. United Health’s revenue increased by 13 percent to $35.8 billion. Revenue attributable to the company’s Optum segment — which includes OptumHealth, OptumInsight and OptumRx — grew 15 percent year-over-year to $12.8 billion.

2. UnitedHealth’s medical loss ratio — the amount the insurer spent on actual healthcare costs — fell to 81.1 percent, down 1.4 percent from the first quarter of fiscal 2014.

3. The company’s net income grew to 1.4 billion, resulting in earnings per share climbing 33 percent year-over-year to $1.46 per share. United Health expects its full-year revenue to be $143 billion, up from its original guidance of $141 billion.

4. UnitedHealth shares have risen 48 percent in the past 12 months, according to Reuters.

5. Generally viewed as a lower cost competitor to other large payers, the healthcare industry keeps close tabs on UnitedHealth. The company has made some major moves in the last year, including plans to combine OptumRx with Schaumburg, Ill.-based Catamaran Corp. as part of a $12.8 billion deal.

More articles on healthcare finance:

Healthcare executives predict 2015 will be a year of financial growth
Fitch: SGR replacement reinforces move toward value-based care
Florida governor to sue feds for withholding hospital funding

Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit

Advertisement

Next Up in Financial Management

Advertisement

Comments are closed.